📢 French company Medincell Corp has been awarded a $6 million grant by global health agency Unitaid to fund the safety testing of its malaria vaccine mdc-STM. This funding comes after significant progress in malaria vaccines, with the R21/Matrix-M vaccine achieving a 75% protective effect in Phase III tests on children. Medincell’s vaccine is an injectable formulation of the antiparasitic ivermectin.
📢 French Company Receives $6m Grant to Combat Malaria
Introduction:
French company Medincell Corp has been awarded a grant of up to $6 million by global health agency Unitaid to fund the safety testing of its malaria vaccine mdc-STM. The funding comes after successful progress in malaria vaccines and aims to support the development of a long-acting injectable formulation of ivermectin, which could help reduce the risk of malaria transmission.
Main points:
- Medincell Corp has been awarded a grant of up to $6 million by Unitaid to fund the safety testing of its malaria vaccine mdc-STM.
- The funding comes after promising progress in malaria vaccines, such as the R21/Matrix-M vaccine from Oxford University.
- mdc-STM is an investigational three-month active injectable formulation of ivermectin that is embedded into Medincell’s co-polymers for continuous release of the drug.
- The grant will support the clinical Phase 1 testing of Medincell’s long-acting injectable candidate.
- Ivermectin, the drug embedded in the co-polymers, eliminates parasites and insects like mosquitoes, which can lower the risk of malaria transmission.
Conclusion:
Unitaid has awarded Medincell Corp a $6 million grant to support the testing and development of its long-acting injectable formulation of ivermectin for malaria prevention. This funding comes after significant progress in malaria vaccines and aims to address the need for new solutions to combat malaria transmission.
